Table 2.
Secondary efficacy endpoints
| Phenoxybenzamine (n = 66) | Doxazosin (n = 68) | P-value | |
|---|---|---|---|
| Systolic blood pressure >160 mmHg | |||
| Frequency, n (%) | 34 (51.5) | 49 (72.1) | .02 |
| Duration (%), mean (IQR) | 0.6 (0.0–4.6) | 3.1 (0.0–8.9) | <.01 |
| Maximum SBP (mmHg), mean (IQR) | 163 (146–188) | 181 (159–203) | <.01 |
| Vasodilating drugs | .02 | ||
| 0, n (%) | 29 (43.9) | 14 (20.6) | |
| 1, n (%) | 21 (31.8) | 23 (33.8) | |
| 2, n (%) | 10 (15.2) | 22 (32.4) | |
| 3, n (%) | 6 (9.1) | 8 (11.7) | |
| 4, n (%) | 0 (0) | 1 (1.5) | |
| Cumulative dosage MgSO4 (g), mean (IQR) | 0 (0–3) | 3 (0–4) | <.01 |
| Cumulative dosage phentolamine (mg), mean (IQR) | 0 (0–0.5) | 0 (0–4) | .16 |
| Mean arterial pressure <60 mmHg | |||
| Frequency, n (%) | 48 (72.7) | 56 (82.4) | .22 |
| Duration (%), mean (IQR) | 5.8 (0.0–16.0) | 6 (1–12) | .82 |
| Minimum MAP (mmHg), mean (IQR) | 53 (44–60) | 51 (46–57) | .36 |
| Vasoconstrictive/inotropic drugs | .46 | ||
| 0, n (%) | 17 (25.8) | 13 (19.1) | |
| 1, n (%) | 24 (36.4) | 27 (39.7) | |
| 2, n (%) | 23 (34.8) | 22 (32.4) | |
| 3, n (%) | 2 (3.0) | 6 (8.8) | |
| Infusion rate of fluids (mL/h), mean (IQR) | 632 (424–945) | 636 (484–896) | .81 |
| Cumulative dosage phenylephrine (µg), mean (IQR) | 0 (0–425) | 0 (0–300) | .98 |
| Cumulative dosage norepinephrine (µg), mean (IQR) | 55 (0–660) | 139 (0–603) | .52 |
| Heart rate >100 bpm | |||
| Frequency, n (%) | 26 (39.4) | 33 (48.5) | .30 |
| Duration (%), mean (IQR) | 0.0 (0.0–2.4) | 0.0 (0.0–3.2) | .47 |
| Maximum HR (bpm), mean (IQR) | 97 (85–115) | 100 (85–115) | .90 |
| Esmolol (mg), mean (IQR) | 0 (0–0) | 0 (0–0) | .61 |
Abbreviations: HR, heart rate; IQR, interquartile range; MAP, mean arterial pressure; SBP, systolic blood pressure.